Inclusion Criteria:

1. Patients must have unresectable, locally advanced, recurrent or metastatic disease of
esophageal cancer.

2. measurable disease by CT scan

3. ECOG performance status of 0 to 2

4. Expected survival of at lease 3months

5. Patients must be HLA-A2402

6. Laboratory values as follow:

- WBC > 2000/mm3,

- Platelet count > 75000/mm3,

- Total bilirubin < 1.5 x the institutional normal upper limits,

- Creatinine < 1.5 x the institutional normal upper limits,

- AST. ALT. ALP < 2.5 x the institutional normal upper limits

7. Able and willing to give valid written informed consent

Exclusion Criteria:

1. Pregnancy (women of childbearing potential:Refusal or inability to use effective
means of contraception)

2. Breastfeeding

3. Active or uncontrolled infection

4. Prior chemotherapy,radiation therapy or immunotherapy within 4 weeks

5. Concurrent treatment with steroid or immunosuppressing agent

6. Patient with peptic ulcer disease

7. Active or uncontrolled other malignancy

8. Other malignancy within 5 years prior to entry into the study, expect for treated
non-melanoma skin cancer and cervical carcinoma in situ

9. Disease to the central nervous system

10. Decision of unsuitableness by principal investigator or physician-in-charge